Luke Pustejovsky is the co-founder & COO of Tactogen, a pharmatech startup developing novel empathogens. Luke believes that robust mental health is a planetary priority, and while therapy is helpful, it’s like digging a ditch with a teaspoon compared to psychedelics and talk therapy combined. That’s why he joined Matt Baggott to create Tactogen, a public benefit corporation whose goal is to make transformative medicines safer, more effective, and more accessible. While most psychedelic medicines have 'mind blowing' qualities and require expensive clinical monitoring, Tactogen is designing their lead molecules to be gentler and safer, which they believe will allow them to be used more flexibly and in more settings.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.